| 000 | 02814cam a2200349 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223031915.0 | ||
| 008 | 180114s2017 ua hh f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aPh.D | ||
| 099 | _aCai01.19.03.Ph.D.2017.Sh.E | ||
| 100 | 0 | _aSherine Abdelmoneim Abotaha | |
| 245 | 1 | 0 |
_aExpression of CYP3A5*3 & CYP1A1*2C polymorphism in adult patient with acute myeloid leukaemia & relation with clinical response / _cSherine Abdelmoneim Abotaha ; Supervised Nahed Abdelwahab Mohamed , Roxan Ezzat Shafik , Nevine Fawzy Shafik |
| 246 | 1 | 5 | _aفى مرضى السرطان اللا ليمفاوى الحاد و علاقته بالا ستجابه الاكلينيكية CYP1A1*2C & CYP3A5*3 تمثيل جين |
| 260 |
_aCairo : _bSherine Abdelmoneim Abotaha , _c2017 |
||
| 300 |
_a158 P. : _bcharts , facsimiles ; _c25cm |
||
| 502 | _aThesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Clinical Pathology | ||
| 520 | _aBackground: Genetic variations are one of the important factors in the development of acute leukemia. Molecular studies have proved that genetic polymorphism of metabolic enzymes influence the risk of a variety of tumors including leukemia. Cytochrome P450 (CYP) enzyme catalyzes the phase I metabolism reaction which metabolize endogenous and exogenous DNA-reactive chemical compounds and xenobiotics which could induce genotoxicity and increase the risk for leukemia. Aim of the study: To detect the frequency of CYP3A5*3 and CYP1A1*2C polymorphisms in Egyptian acute myeloid leukemia (AML) patients and to determine the role of genotypes variants as a risk factor for developing leukemia. Patient and Method: Detection of CYP3A5*3 and CYP1A1*2C polymorphisms using PCR-RFLP method in 70 newly diagnosed AML cases and 30 age and sex comparable healthy controls. Results: we found that CYP3A5*3 polymorphism (3/3) and (1/3) genotypes were significantly elevated in AML group compared to control group (p=0.002). However, no statistical significant differences were found between patients and control group as regard CYP1A1*2C polymorphism. Conclusion: Results suggest that Egyptians carrying CYP3A5*3 polymorphism might have an increased risk of AML emphasizing the significance of effective phase I detoxification in carcinogenesis | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aAcute myeloid leukaemia | |
| 653 | 4 | _aCYP3A5*3 & CYP1A1*2C | |
| 653 | 4 | _aPolymorphism in adult | |
| 700 | 0 |
_aNahed Abdelwahab Mohamed , _eSupervisor |
|
| 700 | 0 |
_aNevine Fawzy Shafik , _eSupervisor |
|
| 700 | 0 |
_aRoxan Ezzat Shafik , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aNazla _eRevisor |
||
| 905 |
_aShimaa _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c64564 _d64564 |
||